以MPLA-CpG佐剂作为候选疫苗评估针对不可分型[细菌名称未给出]外膜囊泡（OMV）的免疫反应。
Evaluation of immunological responses against outer membrane vesicles (OMV) of nontypeable using MPLA-CpG adjuvant as a vaccine candidate.
作者信息
Behrouzi Ava, Mianroodi Reza Arabi, Afrough Parviz, Ayadi Ahmad, Serajian Amirarsalan
机构信息
Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran.
Department of R&D, Research and Production Complex, Pasteur Institute of Iran, Tehran, Iran.
出版信息
Iran J Microbiol. 2020 Oct;12(5):417-423. doi: 10.18502/ijm.v12i5.4602.
BACKGROUND AND OBJECTIVES
Nontypeable (NTHi) are major causes of non-invasive infections, including otitis media and sinusitis and it can also contribute to respiratory infections of all ages. Currently, there is no licensed vaccine against NTHi commercially available. Many studies have been conducted on the use of OMV as a vaccine against NTHi. The purpose of this study is to achieve an immunogenic vaccine against NTHi.
MATERIALS AND METHODS
In this study, standard OMV (ATCC49766) with adjuncts CpG and MPLA was used and after infusion into BALB/c mice, the levels of antibodies and cytokines were measured on serum of immunized mice.
RESULTS
The results showed that total IgG antibody and IgG1 and IgG2a isotypes in OMV immunized mice with mixture of CpG-MPLA adjuvant had a significant increase. Also, the results of cytokines (IL-10, IL-4 and IFN-γ) showed that IL-4 had the highest rate.
CONCLUSION
These findings indicate that OMVs derived from NTHi strains have a high potential to act as a vaccine against NTHi infections.
背景与目的
不可分型流感嗜血杆菌（NTHi）是包括中耳炎和鼻窦炎在内的非侵袭性感染的主要病因，它也可导致各年龄段的呼吸道感染。目前，尚无针对NTHi的已获许可的商业疫苗。关于使用外膜囊泡（OMV）作为抗NTHi疫苗的研究已有很多。本研究的目的是获得一种针对NTHi的具有免疫原性的疫苗。
材料与方法
在本研究中，使用了含有佐剂CpG和MPLA的标准OMV（ATCC49766），将其注入BALB/c小鼠后，检测免疫小鼠血清中的抗体和细胞因子水平。
结果
结果显示，用CpG-MPLA佐剂混合物免疫的小鼠中，总IgG抗体以及IgG1和IgG2a亚型均显著增加。此外，细胞因子（IL-10、IL-4和IFN-γ）的结果显示IL-4的水平最高。
结论
这些发现表明，源自NTHi菌株的OMV具有作为抗NTHi感染疫苗的巨大潜力。
Zotero 插件